TRAW vs. LEXX, TPST, PMN, ACXP, CUE, XLO, AADI, IMRX, VYNE, and EQ
Should you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Lexaria Bioscience (LEXX), Tempest Therapeutics (TPST), ProMIS Neurosciences (PMN), Acurx Pharmaceuticals (ACXP), Cue Biopharma (CUE), Xilio Therapeutics (XLO), Aadi Bioscience (AADI), Immuneering (IMRX), VYNE Therapeutics (VYNE), and Equillium (EQ). These companies are all part of the "pharmaceutical preparations" industry.
Lexaria Bioscience (NASDAQ:LEXX) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.
13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 7.6% of Lexaria Bioscience shares are held by company insiders. Comparatively, 3.3% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Lexaria Bioscience has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -8,033.63%. Traws Pharma's return on equity of -88.39% beat Lexaria Bioscience's return on equity.
Lexaria Bioscience has higher revenue and earnings than Traws Pharma. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.
Lexaria Bioscience has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
In the previous week, Lexaria Bioscience had 4 more articles in the media than Traws Pharma. MarketBeat recorded 6 mentions for Lexaria Bioscience and 2 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 0.90 beat Lexaria Bioscience's score of 0.63 indicating that Lexaria Bioscience is being referred to more favorably in the media.
Lexaria Bioscience received 4 more outperform votes than Traws Pharma when rated by MarketBeat users.
Lexaria Bioscience presently has a consensus price target of $11.00, indicating a potential upside of 225.44%. Given Traws Pharma's higher possible upside, equities analysts clearly believe Lexaria Bioscience is more favorable than Traws Pharma.
Summary
Lexaria Bioscience beats Traws Pharma on 13 of the 16 factors compared between the two stocks.
Get Traws Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Traws Pharma Competitors List
Related Companies and Tools
Free TRAW Stock Alerts